Sagimet Biosciences Shares Jump 30% on Acne Trial Expansion Plans [Yahoo! Finance]
Sagimet Biosciences Inc. (SGMT)
Company Research
Source: Yahoo! Finance
clinical trial of denifanstat for moderate to severe acne in the U.S. during the second half of 2026. The clinical-stage biopharmaceutical company said it is advancing denifanstat into the U.S. acne market, supported by recently reported positive Phase 3 data from China. The upcoming trial will depend on Investigational New Drug clearance, with the company aiming to submit its IND application by mid-2026. Denifanstat Targets Key Drivers of Acne Sagimet explained that denifanstat works by inhibiting fatty acid synthase, helping to lower sebum production while also addressing localized inflammation associated with acne vulgaris. The condition impacts roughly 10 million people annually in the U.S. If approved, the company said denifanstat would be a once-daily oral therapy and the first new oral acne treatment in more than four decades. Positive China Trial Data Supports U.S. Strategy In January 2026, Sagimet's partner Ascletis Bioscience Co. Ltd. reported encouraging topline
Show less
Read more
Impact Snapshot
Event Time:
SGMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMT alerts
High impacting Sagimet Biosciences Inc. news events
Weekly update
A roundup of the hottest topics
SGMT
News
- Sagimet Biosciences (SGMT) had its price target lowered by Guggenheim from $27.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- Why Sagimet Biosciences Stock Is Soaring Today [Yahoo! Finance]Yahoo! Finance
- Why Sagimet Biosciences Stock Is Soaring Today [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common StockGlobeNewswire
- Sagimet Biosciences Provides Strategic and Corporate Updates [Yahoo! Finance]Yahoo! Finance
SGMT
Earnings
- 3/11/26 - Beat
SGMT
Sec Filings
- 4/28/26 - Form 8-K
- 4/28/26 - Form 424B5
- 4/27/26 - Form 8-K
- SGMT's page on the SEC website